New data shows cannabis dominates teens’ substance-related ER visits, often with alcohol or stimulants, urging better screening and intervention for psychosis, vomiting.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.